Institutul Privat de Cercetare Melchisedec pentru Boli Autoimune, Ereditare si Rare
- Address
- Strada Amarandia nr. 21, 200157 Craiova, Romania
Institutul Privat de Cercetare Melchisedec pentru Boli Autoimune, Ereditare si Rare
The Melchisedec Private Research Institute for Autoimmune, Hereditary and Rare Diseases is a specialized clinical research facility dedicated to advancing treatment options for complex and underserved patient populations. The institute combines expertise in rare disease research with comprehensive psychiatric and neurological disorder investigations, contributing to the development of innovative therapeutic approaches.
- Major Depressive Disorder with comorbid sleep disturbances
- Adjunctive therapy trials for treatment-resistant depression
- Long-term efficacy and safety assessments of novel psychiatric medications
The center demonstrates particular strength in evaluating adjunctive treatment strategies for patients who have shown inadequate response to standard antidepressant therapies, including SSRI/SNRI medications. Their research portfolio encompasses both short-term efficacy studies and long-term relapse prevention protocols, with a focus on managing Major Depressive Disorder with Insomnia Symptoms through innovative pharmacological interventions combined with established antidepressant regimens.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Neurocrine Biosciences Inc.2active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Neurocrine Biosciences Inc.3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Institutul Privat de Cercetare Melchisedec pentru Boli Autoimune, Ereditare si Rare
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Azetukalner in Patients with Moderate-to-Severe Major Depressive Disorder | Xenon Pharmaceuticals Inc. | Phase III | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE | 2 | Unknown | 2025-10-07 | 2025-10-22 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.